MedTrace Logo

Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors

NCT07714395 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-07-20

No results posted yet for this study

Summary

This study is being done to test the safety of elraglusib when taken once a day and to assess:

* How the body processes the drug (pharmacokinetics)
* Assess potential effects of the drug on heart rhythm
* Find the highest daily dose that can be given without causing side effects

Conditions

  • Advanced Malignant Solid Tumor

Interventions

DRUG

Elraglusib Oral Tablets

Elraglusib Oral Tablet, 250 mg

Sponsors & Collaborators

  • Actuate Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2029-07-31
Completion
2029-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07714395 on ClinicalTrials.gov